

*Unless otherwise defined herein, capitalized terms in this announcement shall have the same meanings as those defined in the prospectus dated 29 October 2019 (the “**Prospectus**”) issued by TOT BIOPHARM International Company Limited (the “**Company**”).*

Hong Kong Exchanges and Clearing Limited, The Stock Exchange of Hong Kong Limited and Hong Kong Securities Clearing Company Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

This announcement is for information purposes only and does not constitute an offer or an invitation to induce an offer by any person to acquire, purchase or subscribe for any Shares or other securities of the Company. Potential investors should read the Prospectus for detailed information about the Global Offering described below before deciding whether or not to invest in the Offer Shares thereby being offered.

*This announcement is not for release, publication, distribution, directly or indirectly, in or into the United States (including its territories, its possessions and all areas subject to its jurisdiction) or any other jurisdiction where such distribution is prohibited by law. This announcement does not constitute or form a part of any offer to sell or solicitation to purchase or subscribe for securities in Hong Kong, the United States or any other jurisdictions. The Offer Shares have not been, and will not be, registered under the United States Securities Act of 1933, as amended from time to time (the “**U.S. Securities Act**”), or with any securities regulatory authority of any state or other jurisdiction of the United States. The securities may not be offered or sold in the United States except pursuant to registration or an exemption from the registration requirements of the U.S. Securities Act. There will be no public offer of securities in the United States.*

*In connection with the Global Offering, ICBC International Securities Limited, as stabilizing manager (the “**Stabilizing Manager**”), its affiliates or any person acting for it, on behalf of the Underwriters, may effect transactions with a view to stabilizing or supporting the market price of the Shares at a level higher than that which might otherwise prevail in an open market for a limited period after the Listing Date (which is currently expected to be Friday, 8 November 2019). However, there is no obligation on the Stabilizing Manager, its affiliates or any person acting for it, to conduct any such stabilizing action, which, if commenced, will be conducted at the sole and absolute discretion of the Stabilizing Manager, its affiliates or any person acting for it, and may be discontinued at any time. Any such stabilizing activity is required to be brought to an end on the 30th day after the last day for the lodging of applications under the Hong Kong Public Offering. Any market purchases of Shares will be effected in compliance with all applicable laws and regulatory requirements. Such stabilization action, if commenced, may be effected in all jurisdictions where it is permissible to do so, in each case in compliance with all applicable laws, rules and regulatory requirements, including the Securities and Futures (Price Stabilizing) Rules (Cap. 571W of the Laws of Hong Kong), as amended, made under the Securities and Futures Ordinance (Cap. 571 of the Laws of Hong Kong).*

Potential investors should be aware that stabilizing actions cannot be taken to support the price of the Shares for longer than the stabilization period which will begin on the Listing Date and expire on the 30th day after the last day for the lodging of applications under the Hong Kong Public Offering. After this date, no further stabilizing action may be taken, demand for the Shares and the price of the Shares could fall.

Potential investors should note that ICBC International Capital Limited (for itself and on behalf of the Hong Kong Underwriters) shall be entitled, in its sole and absolute discretion, upon giving notice to the Company, to terminate the Hong Kong Underwriting Agreement with immediate effect upon the occurrence of any of the events set out in the paragraph headed “Underwriting – Underwriting Arrangements and Expenses – Hong Kong Public Offering – Grounds for Termination” in the Prospectus at any time prior to 8:00 a.m. (Hong Kong time) on the Listing Date (which is currently expected to be Friday, 8 November 2019).

东曜药业

TOT BIOPHARM International Company Limited

東曜藥業股份有限公司

(Incorporated in Hong Kong with limited liability)

Global Offering

- Total number of Offer Shares : 90,000,000 Shares (subject to the Over-Allotment Option)
- Number of Hong Kong Offer Shares : 9,000,000 Shares
- Number of International Offer Shares : 81,000,000 Shares (subject to the Over-Allotment Option)
- Offer Price : HK\$6.55 per Offer Share, excluding brokerage of 1%, SFC transaction levy of 0.0027% and Stock Exchange trading fee of 0.005%
- Stock code : 1875

Sole Sponsor

ICBC  工银国际

Joint Global Coordinators

ICBC  工银国际

 元大證券(香港)有限公司
Yuanta Securities (Hong Kong) Co., Ltd.

Joint Bookrunners

ICBC  工银国际

 元大證券(香港)有限公司
Yuanta Securities (Hong Kong) Co., Ltd.

 China Renaissance
华兴资本

 光大新鴻基
EVERBRIGHTSUNHUNGKAI

Joint Lead Managers

ICBC  工银国际

 元大證券(香港)有限公司
Yuanta Securities (Hong Kong) Co., Ltd.

 China Renaissance
华兴资本

 光大新鴻基
EVERBRIGHTSUNHUNGKAI

 六福金融
LUKFOOK FINANCIAL